SNY News and Press, Sanofi From 06/14/24

2024-06-14 05:06:33 ET Summary In recent weeks, Sanofi has pleased investors with progress in the development of its pipeline of experimental drugs. On May 20, 2024, SNY announced additional results from a Phase 3 clinical trial that demonstrated Dupixent's greater efficacy in COP...

2024-06-11 07:49:42 ET More on Sanofi, Regeneron, etc. Regeneron Pharmaceuticals, Inc. (REGN) Management presents at Jefferies 2024 Global Healthcare Conference (Transcript) Regeneron Pharmaceuticals Inc (REGN) RBC Capital Markets Global Healthcare Conference (Transcript) ...

2024-06-11 07:23:55 ET More on GSK GSK plc: Long-Term Cash Cow GSK Breathes New Life Into Asthma Treatment With Depemokimab GSK plc (GSK) Q1 2024 Earnings Call Transcript GSK, SpringWorks end collaboration agreement GSK wins FDA nod to expand label fo...

(NewsDirect) Compared to their non-orphan counterparts, orphan drugs have consistently outpaced growth and have become a major part of pharma’s mainstream business. The U.S. FDA's orphan drug designation, established under the Orphan Drug Act of 1983, encourages the development of trea...

2024-06-10 14:58:39 ET More on CSL, bird flu Bird flu death in Mexico linked to strain not seen in humans before Travere, CSL win conditional nod for kidney disease therapy in EU Seeking Alpha’s Quant Rating on CSL Historical earnings data for CSL ...

2024-06-09 09:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-06-07 14:42:51 ET Summary Inhibrx Biosciences, Inc.'s INBRX-109 is a tetravalent drug being developed for the treatment of patients with Ewing Sarcoma and other solid tumor types. It is expected that the Ewing Sarcoma Therapeutics market size could be worth as much as $424.42...

2024-06-07 10:57:58 ET Summary Since Richard Francis became CEO in early 2023, his 'Pivot to Growth' strategy has continued to bear fruit. On April 16, the FDA approved Selarsdi, a biosimilar of Stelara, which earned Johnson & Johnson about $2.45 billion in the first quarter o...

2024-06-06 08:04:56 ET More on Sanofi, Novavax, etc. Novavax: Sanofi Partnership Revitalizes My Magnum Opus Novavax, Inc. (NVAX) Q1 2024 Earnings Call Transcript Novavax Ditches 'Going Concern,' Embraces Sanofi Safety Net (Rating Upgrade) Bird flu death in Me...

I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer PR Newswire ROCKVILLE, Md. , June 6 , 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development and potential commercial...